NRX Pharmaceuticals Inc (NRXP)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $95.58M
Last updated: Nov 17, 2026 at 11:05 AM ET
NRX Pharmaceuticals Inc (NRXP) Earnings: Report Dates and Results
NRX Pharmaceuticals (NRXP) is expected to report earnings on Nov 17, 2026. In the quarter ended Jun 30, 2026, NRX Pharmaceuticals reported EPS of -$0.18, below the -$0.09 estimate. It beat the EPS estimate in 4 of the 8 most recent quarters that had an estimate.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
NRXP has an expected report date of Nov 17, 2026.
NRXP Earnings Call
The latest NRXP earnings call transcript on file is labeled 2026Q2.
Read the 2026Q2 transcriptEarnings History
Of the 16 quarters below that had an estimate, NRXP beat 7, missed 8 and matched 1. The widest gap in the table came in the quarter ended Dec 31, 2025, when EPS landed 329.13% above the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | -$0.18 | -$0.09 | N/A | -100.00% | Miss | N/A | 1 | 0 up, 1 down | Aug 14, 2026 | $1.10M |
| Mar 31, 2026 | -$0.04 | -$0.11 | -$0.11 - -$0.11 | +63.64% | Beat | N/A | 1 | 0 up, 1 down | May 15, 2026 | $1.07M |
| Dec 31, 2025 | $0.18 | -$0.08 | -$0.08 - -$0.08 | +329.13% | Beat | N/A | 1 | 0 up, 1 down | Mar 23, 2026 | $983000 |
| Sep 30, 2025 | -$0.51 | -$0.02 | -$0.13 - $0.16 | N/A | N/A | N/A | 3 | 0 up, 0 down | Nov 14, 2025 | $242000 |
| Jun 30, 2025 | -$0.98 | -$0.23 | -$0.23 - -$0.23 | -326.09% | Miss | N/A | 1 | 0 up, 1 down | Aug 18, 2025 | N/A |
| Mar 31, 2025 | -$0.34 | -$0.53 | N/A | +35.85% | Beat | N/A | 1 | 1 up, 0 down | May 15, 2025 | $4000 |
| Dec 31, 2024 | -$0.77 | -$0.37 | -$0.39 - -$0.20 | -108.11% | Miss | N/A | 2 | 1 up, 0 down | Mar 14, 2025 | $4000 |
| Sep 30, 2024 | -$0.15 | -$0.66 | -$0.66 - -$0.66 | +77.27% | Beat | N/A | 1 | 0 up, 1 down | Nov 14, 2024 | N/A |
| Jun 30, 2024 | -$0.75 | -$0.69 | -$0.81 - -$0.58 | -8.70% | Miss | N/A | 2 | 0 up, 0 down | Aug 14, 2024 | N/A |
| Mar 31, 2024 | -$0.74 | -$0.55 | -$0.55 - -$0.55 | -34.55% | Miss | N/A | 1 | 1 up, 0 down | May 14, 2024 | $8000 |
| Dec 31, 2023 | -$0.50 | -$0.80 | -$0.80 - -$0.50 | +37.50% | Beat | N/A | 3 | 0 up, 0 down | Mar 29, 2024 | $8000 |
| Sep 30, 2023 | -$0.70 | -$1.15 | -$1.20 - -$1.10 | +39.13% | Beat | N/A | 3 | 1 up, 0 down | Nov 13, 2023 | N/A |
| Jun 30, 2023 | -$1.20 | -$1.40 | -$1.50 - -$1.30 | +14.29% | Beat | N/A | 3 | 0 up, 0 down | Aug 14, 2023 | N/A |
| Mar 31, 2023 | -$0.16 | -$0.14 | -$0.15 - -$0.13 | -14.29% | Miss | N/A | 2 | 0 up, 0 down | May 16, 2023 | N/A |
| Dec 31, 2022 | -$1.60 | -$1.45 | -$1.50 - -$1.40 | -10.34% | Miss | N/A | 2 | 0 up, 0 down | Mar 30, 2023 | N/A |
| Sep 30, 2022 | -$1.40 | -$1.40 | -$1.40 - -$1.40 | 0.00% | In line | N/A | 2 | 0 up, 0 down | Nov 14, 2022 | N/A |
| Jun 30, 2022 | -$1.10 | -$1.00 | -$1.00 - -$1.00 | -10.00% | Miss | N/A | 1 | 0 up, 0 down | Aug 15, 2022 | N/A |
| Mar 31, 2022 | -$0.21 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 16, 2022 | N/A |
| Dec 31, 2021 | -$0.53 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 31, 2022 | N/A |
| Sep 30, 2021 | -$0.40 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 16, 2021 | N/A |
| Jun 30, 2021 | -$6.51 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 16, 2021 | N/A |
| Mar 31, 2021 | -$0.16 | N/A | N/A | N/A | N/A | -260.0% | N/A | N/A | Apr 1, 2021 | N/A |
| Dec 31, 2020 | -$2.26 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 31, 2021 | N/A |
| Sep 30, 2020 | -$0.05 | N/A | N/A | N/A | N/A | -600.0% | N/A | N/A | Nov 16, 2020 | N/A |
| Jun 30, 2020 | -$0.06 | N/A | N/A | N/A | N/A | -300.0% | N/A | N/A | Aug 14, 2020 | N/A |
| Mar 31, 2020 | $0.10 | N/A | N/A | N/A | N/A | +400.0% | N/A | N/A | May 15, 2020 | N/A |
| Dec 31, 2019 | -$0.01 | N/A | N/A | N/A | N/A | -131.1% | N/A | N/A | Mar 30, 2020 | N/A |
| Sep 30, 2019 | $0.01 | N/A | N/A | N/A | N/A | -67.8% | N/A | N/A | Nov 14, 2019 | N/A |
| Jun 30, 2019 | $0.03 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 14, 2019 | N/A |
| Mar 31, 2019 | $0.02 | N/A | N/A | N/A | N/A | +16.3% | N/A | N/A | May 15, 2019 | N/A |
| Dec 31, 2018 | $0.03 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 15, 2019 | N/A |
| Sep 30, 2018 | $0.03 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 8, 2018 | N/A |
| Jun 30, 2018 | -$0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 8, 2018 | N/A |
| Mar 31, 2018 | $0.02 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 15, 2018 | N/A |
| Dec 31, 2017 | -$0.12 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 23, 2018 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$1.65, after -$2.41 the year before. It was -$0.12 for the year ended Dec 31, 2017, the oldest of the 9 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$1.65 | N/A |
| Dec 31, 2024 | -$2.41 | N/A |
| Dec 31, 2023 | -$2.56 | N/A |
| Dec 31, 2022 | -$4.31 | N/A |
| Dec 31, 2021 | -$7.60 | N/A |
| Dec 31, 2020 | -$2.27 | -4637.6% |
| Dec 31, 2019 | $0.05 | N/A |
| Dec 31, 2018 | $0.07 | N/A |
| Dec 31, 2017 | -$0.12 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q2 for the period ended Jun 30, 2026, runs about 4,100 words across 7 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q2 | Jun 30, 2026 | 4,145 | 7 | |
| 2026Q1 | Mar 31, 2026 | 4,294 | 7 | |
| 2025Q4 | Dec 31, 2025 | 4,180 | 6 | |
| 2025Q3 | Sep 30, 2025 | 4,536 | 7 | |
| 2025Q2 | Jun 30, 2025 | 5,500 | 8 | |
| 2025Q1 | Mar 31, 2025 | 4,489 | 6 | |
| 2024Q4 | Dec 31, 2024 | 3,870 | 8 | |
| 2024Q3 | Sep 30, 2024 | 5,232 | 8 |
2026Q2 Earnings Call
Opening remarks
Sebastian Gomez Alarcon IR / Moderator Thank you, operator, and welcome, everyone. Before we proceed with the call, I would like to remind everyone that certain statements made during this call are forward-looking statements under U.S. federal securities laws. These statements are subject to risks and uncertainties that could cause actual results to differ materially from historical experience or present expectations. Additional information concerning factors that could cause actual results to differ from statements made on this call is contained in our periodic reports filed with the SEC. The forward-looking statements made during this call speak only as of the date hereof, and the company undertakes no obligation to update or revise the forward-looking statements. Information presented on this call is contained in the press release issued today and in the company's Form 10-Q, which may be accessed from the Investor page of the NRx Pharmaceuticals website. Joining me on today's call is Dr. Jonathan Javitt, our Founder, Chairman and CEO; and Michael Abrams, our Chief Financial Officer. Dr. Javitt will provide an overview of the company's progress during both the first half of the year and second quarter in particular, following which Michael Abrams will review our financial results. Following their prepared remarks, we will address investor questions. I will now turn the call over to Jonathan. Jonathan?
Jonathan Javitt Founder, Chairman & CEO Thank you, Sebastian. Good morning, everyone. Thank you for joining us. The second quarter of 2026 was a major inflection point for our company across multiple key objectives as we advanced our mission to bring hope to vulnerable patients battling depression and suicidal ideation. We continue to drive forward toward those key objectives with quarterly results that include completing the first cycle of a review of our ANDA for preservative-free ketamine with only a single remaining major deficiency to resolve with FDA, advancing the path to approval for NRX-100, supported by White House and Congress guidance to the FDA for the use of real-world evidence to establish comparable or superior efficacy, working in concert with the U.S. military as the prime contractor that's been identified for the SPARC-TMS trial. That's an FDA-approved Phase II/III trial of NRX-101 with robotic TMS that we expect will include 240 patients in our HOPE clinics and at Harvard/McLean together with another 160 patients at military treatment facilities, all funded through the military, and we're still in the contracting process for that. Completing the acquisition of the general assets and the resulting partnership with NIH, to potentially develop the first disease-modifying drug to treat ALS; and finally, continuing growth and development at the HOPE Therapeutics clinic footprint with expanded operations in Florida. Let me start with the ANDA for preservative-free ketamine.
Frequently Asked Questions About NRXP
When is NRX Pharmaceuticals's next earnings date?
NRX Pharmaceuticals's next earnings report is expected for Nov 17, 2026.
Did NRXP beat earnings estimates last quarter?
No. NRX Pharmaceuticals reported EPS of -$0.18 for the quarter ended Jun 30, 2026, below the -$0.09 estimate by 100.00%.
What EPS do analysts expect from NRXP next quarter?
The consensus EPS estimate for NRX Pharmaceuticals for the quarter ending Dec 31, 2026 is -$0.23 from 7 analysts, with estimates from -$0.49 to -$0.11.
How often does NRXP beat earnings estimates?
NRX Pharmaceuticals beat the EPS estimate in 4 of the 8 most recent quarters that had an estimate, with an average surprise of -4.63%.
NRXP pages: Overview, Earnings, Forecast, Financials, Competitors